Merck
-

Phase 3 Victory for Moderna and Merck’s mRNA Cancer Vaccine Signals Paradigm Shift in Personalized Oncology
Moderna and Merck’s mRNA cancer vaccine combined with Keytruda met Phase 3 goals in melanoma, driving stock surges and paving the way for FDA filing.
